nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—kidney cancer	0.179	0.345	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Everolimus—kidney cancer	0.0461	0.0886	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Pazopanib—kidney cancer	0.0403	0.0776	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Temsirolimus—kidney cancer	0.0311	0.0599	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Capecitabine—kidney cancer	0.0293	0.0564	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Erlotinib—kidney cancer	0.0288	0.0553	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Paclitaxel—kidney cancer	0.0263	0.0507	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Sorafenib—kidney cancer	0.0234	0.045	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Paclitaxel—kidney cancer	0.0184	0.0353	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Pazopanib—kidney cancer	0.0163	0.0315	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Sorafenib—kidney cancer	0.0163	0.0314	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Erlotinib—kidney cancer	0.0117	0.0224	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Paclitaxel—kidney cancer	0.0107	0.0205	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Sorafenib—kidney cancer	0.00948	0.0183	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vinblastine—kidney cancer	0.00936	0.018	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vincristine—kidney cancer	0.00921	0.0177	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Sunitinib—kidney cancer	0.00768	0.0148	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—kidney cancer	0.00575	0.0111	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—gonad—kidney cancer	0.00401	0.119	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—urine—kidney cancer	0.00301	0.0893	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—urine—kidney cancer	0.00299	0.0886	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vincristine—Vinblastine—kidney cancer	0.00247	0.554	CbGdCrCtD
Medroxyprogesterone Acetate—CYP3A4—urine—kidney cancer	0.00228	0.0675	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—nephron tubule—kidney cancer	0.00207	0.0615	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vincristine—kidney cancer	0.00199	0.446	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—cortex of kidney—kidney cancer	0.00177	0.0526	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—cardiac atrium—kidney cancer	0.00169	0.0501	CbGeAlD
Medroxyprogesterone Acetate—SHBG—gonad—kidney cancer	0.00127	0.0377	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—kidney cancer	0.00102	0.0302	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—kidney cancer	0.000998	0.0296	CbGeAlD
Medroxyprogesterone Acetate—AR—kidney—kidney cancer	0.000983	0.0292	CbGeAlD
Medroxyprogesterone Acetate—ESR1—kidney—kidney cancer	0.000965	0.0286	CbGeAlD
Medroxyprogesterone Acetate—AR—cortex of kidney—kidney cancer	0.000958	0.0284	CbGeAlD
Medroxyprogesterone Acetate—Hydrocortisone—ANXA1—kidney cancer	0.000921	0.313	CrCbGaD
Medroxyprogesterone Acetate—AR—gonad—kidney cancer	0.000912	0.0271	CbGeAlD
Medroxyprogesterone Acetate—AR—cardiac atrium—kidney cancer	0.000911	0.027	CbGeAlD
Medroxyprogesterone Acetate—ESR1—gonad—kidney cancer	0.000895	0.0266	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—renal system—kidney cancer	0.000823	0.0244	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—nephron tubule—kidney cancer	0.00081	0.024	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—kidney—kidney cancer	0.000795	0.0236	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—kidney cancer	0.000737	0.0218	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—kidney—kidney cancer	0.000712	0.0211	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—cortex of kidney—kidney cancer	0.000694	0.0206	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—gonad—kidney cancer	0.000661	0.0196	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—cardiac atrium—kidney cancer	0.00066	0.0196	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—BCHE—kidney cancer	0.000568	0.193	CrCbGaD
Medroxyprogesterone Acetate—CYP3A4—renal system—kidney cancer	0.000557	0.0165	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—kidney—kidney cancer	0.000539	0.016	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—kidney cancer	0.000262	0.0889	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—ABCB1—kidney cancer	0.000255	0.0865	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—ABCB1—kidney cancer	0.000195	0.0663	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1A1—kidney cancer	0.000161	0.0548	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—ABCB1—kidney cancer	0.000158	0.0538	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1A1—kidney cancer	0.000153	0.0518	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—ABCB1—kidney cancer	0.000105	0.0357	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ABCB1—kidney cancer	8.57e-05	0.0291	CrCbGaD
Medroxyprogesterone Acetate—Dizziness—Sorafenib—kidney cancer	8.11e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ABCB1—kidney cancer	8.11e-05	0.0275	CrCbGaD
Medroxyprogesterone Acetate—Constipation—Gemcitabine—kidney cancer	8.1e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Erlotinib—kidney cancer	8.1e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Capecitabine—kidney cancer	8.09e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Paclitaxel—kidney cancer	8.09e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Doxorubicin—kidney cancer	8.08e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Sunitinib—kidney cancer	8.08e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Doxorubicin—kidney cancer	8.02e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Capecitabine—kidney cancer	8.02e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Dactinomycin—kidney cancer	8.02e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Paclitaxel—kidney cancer	8e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Doxorubicin—kidney cancer	7.99e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Capecitabine—kidney cancer	7.97e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Capecitabine—kidney cancer	7.97e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Paclitaxel—kidney cancer	7.93e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Paclitaxel—kidney cancer	7.93e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Vincristine—kidney cancer	7.89e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Vincristine—kidney cancer	7.89e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Paclitaxel—kidney cancer	7.88e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Capecitabine—kidney cancer	7.86e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Doxorubicin—kidney cancer	7.82e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Capecitabine—kidney cancer	7.81e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Sunitinib—kidney cancer	7.8e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Gemcitabine—kidney cancer	7.8e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Paclitaxel—kidney cancer	7.8e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Sorafenib—kidney cancer	7.8e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Doxorubicin—kidney cancer	7.79e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Paclitaxel—kidney cancer	7.78e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Doxorubicin—kidney cancer	7.77e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Paclitaxel—kidney cancer	7.76e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Paclitaxel—kidney cancer	7.74e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Sorafenib—kidney cancer	7.73e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Sorafenib—kidney cancer	7.73e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Capecitabine—kidney cancer	7.71e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Doxorubicin—kidney cancer	7.71e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Paclitaxel—kidney cancer	7.7e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Sorafenib—kidney cancer	7.68e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Capecitabine—kidney cancer	7.67e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Paclitaxel—kidney cancer	7.67e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Dactinomycin—kidney cancer	7.65e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Doxorubicin—kidney cancer	7.63e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Paclitaxel—kidney cancer	7.56e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Doxorubicin—kidney cancer	7.53e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Doxorubicin—kidney cancer	7.53e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Sunitinib—kidney cancer	7.5e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Gemcitabine—kidney cancer	7.49e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Tremor—Capecitabine—kidney cancer	7.47e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Sunitinib—kidney cancer	7.44e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Sunitinib—kidney cancer	7.44e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Doxorubicin—kidney cancer	7.43e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Paclitaxel—kidney cancer	7.41e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Capecitabine—kidney cancer	7.4e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Sunitinib—kidney cancer	7.39e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—kidney cancer	7.38e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—kidney cancer	7.38e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—kidney cancer	7.38e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Capecitabine—kidney cancer	7.37e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Vincristine—kidney cancer	7.36e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Sorafenib—kidney cancer	7.29e-05	0.000223	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.22e-05	0.000221	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Capecitabine—kidney cancer	7.19e-05	0.00022	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Paclitaxel—kidney cancer	7.17e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Capecitabine—kidney cancer	7.16e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Vincristine—kidney cancer	7.16e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Capecitabine—kidney cancer	7.15e-05	0.000218	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Paclitaxel—kidney cancer	7.12e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—kidney cancer	7.1e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—kidney cancer	7.09e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Paclitaxel—kidney cancer	7.07e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Paclitaxel—kidney cancer	7.05e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Capecitabine—kidney cancer	7.05e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Dactinomycin—kidney cancer	7.05e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Sunitinib—kidney cancer	7.01e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Capecitabine—kidney cancer	7.01e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Paclitaxel—kidney cancer	6.98e-05	0.000213	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—kidney cancer	6.9e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Paclitaxel—kidney cancer	6.89e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.86e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.85e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Paclitaxel—kidney cancer	6.84e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Vincristine—kidney cancer	6.83e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—kidney cancer	6.81e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Gemcitabine—kidney cancer	6.79e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Capecitabine—kidney cancer	6.79e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Capecitabine—kidney cancer	6.79e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Capecitabine—kidney cancer	6.79e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Paclitaxel—kidney cancer	6.78e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Capecitabine—kidney cancer	6.76e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.74e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—kidney cancer	6.71e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Capecitabine—kidney cancer	6.71e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Gemcitabine—kidney cancer	6.7e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—kidney cancer	6.67e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—kidney cancer	6.65e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Capecitabine—kidney cancer	6.64e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—kidney cancer	6.64e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Vincristine—kidney cancer	6.6e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—kidney cancer	6.58e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—kidney cancer	6.58e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—kidney cancer	6.58e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Capecitabine—kidney cancer	6.56e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Paclitaxel—kidney cancer	6.53e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Capecitabine—kidney cancer	6.51e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Paclitaxel—kidney cancer	6.48e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Gemcitabine—kidney cancer	6.48e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Capecitabine—kidney cancer	6.46e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—kidney cancer	6.45e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—kidney cancer	6.41e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—kidney cancer	6.41e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Capecitabine—kidney cancer	6.4e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—kidney cancer	6.39e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Capecitabine—kidney cancer	6.38e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Capecitabine—kidney cancer	6.37e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Capecitabine—kidney cancer	6.35e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vincristine—kidney cancer	6.35e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Capecitabine—kidney cancer	6.32e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—kidney cancer	6.3e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Paclitaxel—kidney cancer	6.3e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vincristine—kidney cancer	6.29e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Capecitabine—kidney cancer	6.29e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vincristine—kidney cancer	6.29e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Paclitaxel—kidney cancer	6.27e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Paclitaxel—kidney cancer	6.27e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vincristine—kidney cancer	6.25e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—kidney cancer	6.22e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—kidney cancer	6.2e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Capecitabine—kidney cancer	6.2e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—kidney cancer	6.17e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Capecitabine—kidney cancer	6.08e-05	0.000186	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Gemcitabine—kidney cancer	6.02e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—kidney cancer	6.01e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Gemcitabine—kidney cancer	5.97e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Gemcitabine—kidney cancer	5.97e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—kidney cancer	5.93e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Gemcitabine—kidney cancer	5.93e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vincristine—kidney cancer	5.93e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.93e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—kidney cancer	5.9e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—kidney cancer	5.9e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Capecitabine—kidney cancer	5.89e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—kidney cancer	5.86e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Capecitabine—kidney cancer	5.84e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Paclitaxel—kidney cancer	5.84e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—kidney cancer	5.83e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—kidney cancer	5.82e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—kidney cancer	5.8e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Capecitabine—kidney cancer	5.8e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—kidney cancer	5.79e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Capecitabine—kidney cancer	5.73e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—kidney cancer	5.69e-05	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Paclitaxel—kidney cancer	5.69e-05	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Capecitabine—kidney cancer	5.66e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Gemcitabine—kidney cancer	5.63e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Capecitabine—kidney cancer	5.62e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Capecitabine—kidney cancer	5.61e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Paclitaxel—kidney cancer	5.61e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—kidney cancer	5.58e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Capecitabine—kidney cancer	5.56e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—kidney cancer	5.52e-05	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—kidney cancer	5.5e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—kidney cancer	5.48e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Paclitaxel—kidney cancer	5.43e-05	0.000166	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Capecitabine—kidney cancer	5.36e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—kidney cancer	5.36e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—kidney cancer	5.33e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Capecitabine—kidney cancer	5.32e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—kidney cancer	5.32e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—kidney cancer	5.3e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Paclitaxel—kidney cancer	5.24e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—kidney cancer	5.22e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—kidney cancer	5.17e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Capecitabine—kidney cancer	5.17e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Capecitabine—kidney cancer	5.14e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Capecitabine—kidney cancer	5.14e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—kidney cancer	5.14e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—kidney cancer	5.14e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—kidney cancer	5.06e-05	0.000155	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—kidney cancer	5.04e-05	0.000154	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Paclitaxel—kidney cancer	5.04e-05	0.000154	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—kidney cancer	5.03e-05	0.000154	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Paclitaxel—kidney cancer	5e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Paclitaxel—kidney cancer	4.99e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—kidney cancer	4.99e-05	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—kidney cancer	4.97e-05	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Paclitaxel—kidney cancer	4.97e-05	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—kidney cancer	4.94e-05	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Capecitabine—kidney cancer	4.79e-05	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—kidney cancer	4.77e-05	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—kidney cancer	4.75e-05	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—kidney cancer	4.72e-05	0.000144	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Paclitaxel—kidney cancer	4.71e-05	0.000144	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Capecitabine—kidney cancer	4.67e-05	0.000143	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—kidney cancer	4.63e-05	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—kidney cancer	4.62e-05	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—kidney cancer	4.61e-05	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Capecitabine—kidney cancer	4.6e-05	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—kidney cancer	4.54e-05	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—kidney cancer	4.52e-05	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—kidney cancer	4.45e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Capecitabine—kidney cancer	4.45e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—kidney cancer	4.38e-05	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—kidney cancer	4.38e-05	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—kidney cancer	4.38e-05	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—kidney cancer	4.36e-05	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.35e-05	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—kidney cancer	4.32e-05	0.000132	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Capecitabine—kidney cancer	4.3e-05	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—kidney cancer	4.28e-05	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—kidney cancer	4.23e-05	0.000129	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—kidney cancer	4.19e-05	0.000128	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—kidney cancer	4.19e-05	0.000128	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—kidney cancer	4.17e-05	0.000127	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Capecitabine—kidney cancer	4.14e-05	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—kidney cancer	4.13e-05	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—kidney cancer	4.11e-05	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—kidney cancer	4.11e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Capecitabine—kidney cancer	4.1e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Capecitabine—kidney cancer	4.1e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—kidney cancer	4.09e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Capecitabine—kidney cancer	4.08e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—kidney cancer	4.07e-05	0.000124	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—kidney cancer	4.05e-05	0.000124	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—kidney cancer	4e-05	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—kidney cancer	3.92e-05	0.00012	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Capecitabine—kidney cancer	3.87e-05	0.000118	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.82e-05	0.000117	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—kidney cancer	3.79e-05	0.000116	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—kidney cancer	3.77e-05	0.000115	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—kidney cancer	3.74e-05	0.000114	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—kidney cancer	3.73e-05	0.000114	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—kidney cancer	3.69e-05	0.000113	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—kidney cancer	3.65e-05	0.000111	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.62e-05	0.000111	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—kidney cancer	3.62e-05	0.00011	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—kidney cancer	3.59e-05	0.00011	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—kidney cancer	3.46e-05	0.000106	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—kidney cancer	3.43e-05	0.000105	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—kidney cancer	3.33e-05	0.000102	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—kidney cancer	3.32e-05	0.000101	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—kidney cancer	3.32e-05	0.000101	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—kidney cancer	3.09e-05	9.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—kidney cancer	3.01e-05	9.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—kidney cancer	2.97e-05	9.07e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—kidney cancer	2.87e-05	8.77e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—FH—kidney cancer	2.83e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—APRT—kidney cancer	2.83e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.82e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN2B—kidney cancer	2.82e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.78e-05	0.000249	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—kidney cancer	2.77e-05	8.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.76e-05	0.000247	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.76e-05	0.000247	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—kidney cancer	2.75e-05	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PSMD7—kidney cancer	2.75e-05	0.000245	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1R—kidney cancer	2.74e-05	0.000245	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUNB—kidney cancer	2.73e-05	0.000244	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PAK1—kidney cancer	2.73e-05	0.000244	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PSMD7—kidney cancer	2.71e-05	0.000242	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.68e-05	0.000239	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.67e-05	0.000239	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—kidney cancer	2.67e-05	8.15e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—BRAF—kidney cancer	2.67e-05	0.000238	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GPC3—kidney cancer	2.66e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Doxorubicin—kidney cancer	2.64e-05	8.08e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—kidney cancer	2.64e-05	8.07e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.64e-05	0.000236	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Doxorubicin—kidney cancer	2.63e-05	8.03e-05	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—CDKN2B—kidney cancer	2.61e-05	0.000233	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CA2—kidney cancer	2.58e-05	0.000231	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.58e-05	0.00023	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALAD—kidney cancer	2.52e-05	0.000225	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP2—kidney cancer	2.51e-05	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKAP13—kidney cancer	2.51e-05	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—kidney cancer	2.49e-05	7.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.49e-05	0.000223	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPAT—kidney cancer	2.47e-05	0.000221	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.47e-05	0.000221	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—JUNB—kidney cancer	2.47e-05	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ST3GAL2—kidney cancer	2.46e-05	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.44e-05	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—JUNB—kidney cancer	2.43e-05	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.42e-05	0.000216	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALDH1A1—kidney cancer	2.4e-05	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ACY1—kidney cancer	2.35e-05	0.00021	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC5A3—kidney cancer	2.3e-05	0.000206	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PGK1—kidney cancer	2.3e-05	0.000206	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—APRT—kidney cancer	2.3e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—FH—kidney cancer	2.3e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GRB7—kidney cancer	2.29e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—POMC—kidney cancer	2.26e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—LDHB—kidney cancer	2.26e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HIF1A—kidney cancer	2.25e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TSC2—kidney cancer	2.25e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.25e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PIK3CA—kidney cancer	2.25e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF2—kidney cancer	2.23e-05	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—RAF1—kidney cancer	2.23e-05	0.000199	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN2B—kidney cancer	2.22e-05	0.000199	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—kidney cancer	2.2e-05	0.000197	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTOR—kidney cancer	2.17e-05	0.000194	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CD4—kidney cancer	2.17e-05	0.000194	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GPC3—kidney cancer	2.16e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1R—kidney cancer	2.16e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KDR—kidney cancer	2.16e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—kidney cancer	2.15e-05	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ITPR2—kidney cancer	2.13e-05	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CA2—kidney cancer	2.1e-05	0.000188	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—kidney cancer	2.1e-05	0.000187	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALAD—kidney cancer	2.05e-05	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1B—kidney cancer	2.04e-05	0.000182	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CDKN2B—kidney cancer	2.01e-05	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PDHB—kidney cancer	2e-05	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ST3GAL2—kidney cancer	2e-05	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—POMC—kidney cancer	2e-05	0.000178	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—APC—kidney cancer	1.99e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KIT—kidney cancer	1.99e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CDKN2B—kidney cancer	1.98e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CA9—kidney cancer	1.96e-05	0.000175	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.96e-05	0.000175	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNA1—kidney cancer	1.93e-05	0.000173	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—kidney cancer	1.93e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EIF4EBP1—kidney cancer	1.92e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HSPB1—kidney cancer	1.92e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.91e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—POMC—kidney cancer	1.89e-05	0.000169	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CCBL1—kidney cancer	1.88e-05	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTEN—kidney cancer	1.88e-05	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PGK1—kidney cancer	1.87e-05	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.87e-05	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—BRAF—kidney cancer	1.87e-05	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—LDHB—kidney cancer	1.84e-05	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—kidney cancer	1.8e-05	0.000161	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PSMD7—kidney cancer	1.79e-05	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ANXA1—kidney cancer	1.79e-05	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TSC1—kidney cancer	1.79e-05	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HIF1A—kidney cancer	1.78e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TSC2—kidney cancer	1.77e-05	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FLT1—kidney cancer	1.73e-05	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KDR—kidney cancer	1.7e-05	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CRABP1—kidney cancer	1.67e-05	0.000149	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.63e-05	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPAT—kidney cancer	1.63e-05	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—kidney cancer	1.62e-05	0.000144	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MAPK3—kidney cancer	1.6e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PAK1—kidney cancer	1.6e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUNB—kidney cancer	1.6e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CA9—kidney cancer	1.59e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—kidney cancer	1.59e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTEN—kidney cancer	1.57e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KIT—kidney cancer	1.57e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—APC—kidney cancer	1.57e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—kidney cancer	1.56e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RAF1—kidney cancer	1.56e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.56e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RELA—kidney cancer	1.55e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ITPR2—kidney cancer	1.55e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—kidney cancer	1.54e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MAPK1—kidney cancer	1.53e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MTOR—kidney cancer	1.52e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—FH—kidney cancer	1.52e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—APRT—kidney cancer	1.52e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—POMC—kidney cancer	1.49e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—BRAF—kidney cancer	1.47e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—kidney cancer	1.44e-05	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1B—kidney cancer	1.43e-05	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.43e-05	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GPC3—kidney cancer	1.43e-05	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTT1—kidney cancer	1.41e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ACHE—kidney cancer	1.41e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL2—kidney cancer	1.4e-05	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA2—kidney cancer	1.39e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MAPK3—kidney cancer	1.36e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—kidney cancer	1.36e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—JUN—kidney cancer	1.36e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CRABP1—kidney cancer	1.36e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALAD—kidney cancer	1.35e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—kidney cancer	1.35e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SCARB1—kidney cancer	1.34e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—kidney cancer	1.33e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CA—kidney cancer	1.32e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS1—kidney cancer	1.32e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.32e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTEN—kidney cancer	1.32e-05	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF2—kidney cancer	1.31e-05	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN2B—kidney cancer	1.31e-05	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PSMD7—kidney cancer	1.3e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.29e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1R—kidney cancer	1.27e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ITPR2—kidney cancer	1.26e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PGK1—kidney cancer	1.24e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.24e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—BCHE—kidney cancer	1.23e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RAF1—kidney cancer	1.23e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RELA—kidney cancer	1.22e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—kidney cancer	1.22e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC5A5—kidney cancer	1.22e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LDHB—kidney cancer	1.21e-05	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MTOR—kidney cancer	1.2e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—kidney cancer	1.19e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC2A1—kidney cancer	1.17e-05	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.16e-05	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTT1—kidney cancer	1.15e-05	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ACHE—kidney cancer	1.15e-05	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.14e-05	0.000102	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—kidney cancer	1.13e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK3—kidney cancer	1.12e-05	0.0001	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—kidney cancer	1.11e-05	9.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—kidney cancer	1.1e-05	9.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—kidney cancer	1.09e-05	9.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SCARB1—kidney cancer	1.09e-05	9.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS1—kidney cancer	1.08e-05	9.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—kidney cancer	1.07e-05	9.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUN—kidney cancer	1.07e-05	9.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK1—kidney cancer	1.07e-05	9.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—kidney cancer	1.06e-05	9.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PSMD7—kidney cancer	1.06e-05	9.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA9—kidney cancer	1.05e-05	9.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HIF1A—kidney cancer	1.04e-05	9.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TSC2—kidney cancer	1.04e-05	9.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MAPK3—kidney cancer	1.04e-05	9.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—kidney cancer	1.04e-05	9.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—kidney cancer	1.01e-05	9.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—kidney cancer	1.01e-05	9.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—BCHE—kidney cancer	1e-05	8.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—kidney cancer	9.98e-06	8.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.93e-06	8.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC5A5—kidney cancer	9.89e-06	8.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—kidney cancer	9.79e-06	8.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC2A1—kidney cancer	9.55e-06	8.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—kidney cancer	9.37e-06	8.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—kidney cancer	9.28e-06	8.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.27e-06	8.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ABCB1—kidney cancer	9.26e-06	8.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIT—kidney cancer	9.2e-06	8.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APC—kidney cancer	9.2e-06	8.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTM1—kidney cancer	8.99e-06	8.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—kidney cancer	8.98e-06	8.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CRABP1—kidney cancer	8.94e-06	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK3—kidney cancer	8.86e-06	7.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—POMC—kidney cancer	8.75e-06	7.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—BRAF—kidney cancer	8.64e-06	7.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—kidney cancer	8.62e-06	7.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1A1—kidney cancer	8.53e-06	7.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK1—kidney cancer	8.43e-06	7.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ITPR2—kidney cancer	8.31e-06	7.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.08e-06	7.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MAPK3—kidney cancer	8e-06	7.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—kidney cancer	7.97e-06	7.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—kidney cancer	7.97e-06	7.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MAPK3—kidney cancer	7.88e-06	7.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—kidney cancer	7.78e-06	6.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—kidney cancer	7.66e-06	6.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTT1—kidney cancer	7.58e-06	6.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ACHE—kidney cancer	7.58e-06	6.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ABCB1—kidney cancer	7.54e-06	6.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTM1—kidney cancer	7.32e-06	6.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—kidney cancer	7.32e-06	6.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RAF1—kidney cancer	7.22e-06	6.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RELA—kidney cancer	7.18e-06	6.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SCARB1—kidney cancer	7.17e-06	6.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—kidney cancer	7.14e-06	6.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS1—kidney cancer	7.1e-06	6.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—kidney cancer	7.08e-06	6.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTOR—kidney cancer	7.05e-06	6.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7e-06	6.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PSMD7—kidney cancer	6.96e-06	6.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.94e-06	6.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—kidney cancer	6.61e-06	5.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—BCHE—kidney cancer	6.6e-06	5.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.52e-06	5.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—kidney cancer	6.47e-06	5.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—POMC—kidney cancer	6.36e-06	5.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—kidney cancer	6.31e-06	5.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.3e-06	5.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUN—kidney cancer	6.29e-06	5.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—kidney cancer	6.25e-06	5.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—kidney cancer	6.09e-06	5.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.7e-06	5.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—kidney cancer	5.5e-06	4.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—kidney cancer	5.25e-06	4.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK3—kidney cancer	5.2e-06	4.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—POMC—kidney cancer	5.17e-06	4.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—kidney cancer	5.07e-06	4.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—kidney cancer	5.06e-06	4.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCB1—kidney cancer	4.97e-06	4.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK1—kidney cancer	4.95e-06	4.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTM1—kidney cancer	4.83e-06	4.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—kidney cancer	4.68e-06	4.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.58e-06	4.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—kidney cancer	4.42e-06	3.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—kidney cancer	4.3e-06	3.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—kidney cancer	4.16e-06	3.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—kidney cancer	4.13e-06	3.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—kidney cancer	3.6e-06	3.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—POMC—kidney cancer	3.41e-06	3.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—kidney cancer	3.12e-06	2.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—kidney cancer	2.72e-06	2.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.54e-06	2.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—kidney cancer	2.37e-06	2.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.67e-06	1.5e-05	CbGpPWpGaD
